Clinical Trials Logo

Clinical Trial Summary

Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-810 in healthy adult subjects.


Clinical Trial Description

This is a single ascending dose study of ARCT-810 in which approximately 30 subjects are planned to be enrolled. The length of each study participant is approximately 8 weeks from screening to last study visit. Study participants will be allocated to one of the five different study groups (also called cohorts), to test different doses of ARCT-810. There will be 6 participants in each group. Within each cohort, subjects will be randomized 2:1 to receive ARCT-810 or placebo as an IV infusion. ;


Study Design


Related Conditions & MeSH terms

  • Ornithine Transcarbamylase Deficiency

NCT number NCT04416126
Study type Interventional
Source Arcturus Therapeutics, Inc.
Contact
Status Completed
Phase Phase 1
Start date June 1, 2020
Completion date December 9, 2020

See also
  Status Clinical Trial Phase
Completed NCT01569568 - Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Terminated NCT04717453 - Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
Recruiting NCT05910151 - Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT04612764 - Liver Disease in Urea Cycle Disorders
Active, not recruiting NCT04442347 - Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency Phase 1
Not yet recruiting NCT02670889 - Urease Inhibitor Drug Treatment for Urea Cycle Disorders Phase 1/Phase 2
Recruiting NCT05092685 - Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn Phase 1/Phase 2
Completed NCT00472732 - Neurologic Injuries in Adults With Urea Cycle Disorders N/A
Terminated NCT04909346 - Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
Recruiting NCT05526066 - Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 Phase 2
Completed NCT00718627 - Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders Phase 2
Recruiting NCT04908319 - Hepatic Histopathology in Urea Cycle Disorders
Withdrawn NCT03767270 - Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency Phase 1/Phase 2
Completed NCT04269122 - A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
Recruiting NCT06255782 - An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency (OTC-HOPE) Phase 1/Phase 2